lercanidipine has been researched along with benidipine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bisenieks, E; Duburs, G; Gall Troselj, K; Krauze, A; Poikans, J; Velena, A; Zarkovic, N | 1 |
| Ding, L; Jiang, P; Li, L; Liu, S; Lu, W; Xu, X; Yang, C; Zhou, P | 1 |
1 review(s) available for lercanidipine and benidipine
| Article | Year |
|---|---|
1,4-Dihydropyridine Derivatives: Dihydronicotinamide Analogues-Model Compounds Targeting Oxidative Stress.
Topics: Amlodipine; Animals; Antioxidants; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cattle; Dihydropyridines; Epithelial Cells; Humans; Hydrogen; Lipoproteins, LDL; Mice; Microsomes; Mitochondria; Niacinamide; Nifedipine; Nitrobenzenes; Oxidants; Oxidative Stress; Piperazines | 2016 |
1 other study(ies) available for lercanidipine and benidipine
| Article | Year |
|---|---|
T-type calcium channels blockers inhibit HSV-2 infection at the late stage of genome replication.
Topics: Animals; Antiviral Agents; Calcium Channel Blockers; Calcium Channels, T-Type; Calcium Signaling; Chlorocebus aethiops; Dihydropyridines; Gene Expression Regulation, Viral; HeLa Cells; Herpes Genitalis; Herpesvirus 2, Human; Host-Pathogen Interactions; Humans; Piperazines; Vero Cells; Virus Replication | 2021 |